Sugi Predict

Sugi Predict / Compounds / SCHEMBL503666

SCHEMBL503666

SCHEMBL503666

O=C(O)CCCc1ccc(C(=O)c2ccccc2C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ HDAC3 O15379 1/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ ADRA1A P35348 1/20 0.61
▸ HDAC4 P56524 1/20 0.61
▸ SLC6A3 Q01959 1/20 0.61
▸ HDAC7 Q8WUI4 1/20 0.61
▸ HDAC2 Q92769 1/20 0.61
▸ HDAC10 Q969S8 1/20 0.61
▸ HDAC11 Q96DB2 1/20 0.61
▸ HDAC8 Q9BY41 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ HDAC9 Q9UKV0 1/20 0.61
▸ HDAC5 Q9UQL6 1/20 0.61
▸ AKR1C3 P42330 3/20 0.58
▸ HSD17B10 Q99714 2/20 0.57
▸ CDC25B P30305 2/20 0.56
▸ ATM Q13315 1/20 0.56
▸ NR4A1 P22736 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9808816 0.85 HDAC8 (0.71) HDAC1SMN1; SMN2HDAC3MAPK1ADRA1A
SCHEMBL28111022 0.84 RARB (0.59) AKR1C3CDC25BATMNR4A1
SCHEMBL2944041 0.83 PLK1 (0.64) AKR1C3CDC25BATMNR4A1MAPT
SCHEMBL918747 0.82 PLK1 (0.66) AKR1C3MAPTALDH1A1
SCHEMBL28013663 0.81 AKR1C3 (0.62) AKR1C3HSD17B10CDC25BATMNR4A1
SCHEMBL28208994 0.80 MAPT (0.70) HDAC1SMN1; SMN2HDAC3MAPK1ADRA1A
SCHEMBL14124724 0.80 AKR1C3 (0.70) AKR1C3HSD17B10CDC25BATMNR4A1
SCHEMBL803658 0.79 HSD17B10 (0.72) HDAC1SMN1; SMN2HDAC3MAPK1ADRA1A
SCHEMBL27524893 0.79 AKR1C3 (0.91) AKR1C3HSD17B10CDC25BATMNR4A1
SCHEMBL14124752 0.78 AKR1C3 (0.74) AKR1C3HSD17B10CDC25BATMNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 — — US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 — — US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 — — US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 — — US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 — — WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 — — US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 — — US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 — — US claimed
EP-0667246-A1 Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds XEROX CORPORATION (US) 1995-08-16 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS HDAC1 1959/4885SMN1; SMN2 4271/4885HDAC3 3090/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HDAC1 1959/4885SMN1; SMN2 4271/4885HDAC3 3090/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 HDAC1 1458/4885SMN1; SMN2 4149/4885HDAC3 1033/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 HDAC1 553/4885SMN1; SMN2 3422/4885HDAC3 849/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HDAC1 1959/4885SMN1; SMN2 4271/4885HDAC3 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.